Mainz Biomed N.V. has announced the next phase in its PancAlert project, which aims to develop a non-invasive blood test for early pancreatic cancer detection. Following a successful discovery ...
Mainz Biomed NV has launched the eAArly DETECT 2 feasibility study, aimed at validating previous results on advanced adenomas using a large population of approximately 2,000 average risk patients.
The feasibility, validity and reliability of the Time Trade-Off (TTO) and Visual Analogue Scale (VAS) methods in obtaining preference values for health states were compared in a random sample of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback